University Startups Demo Day in Washington, DC
New Mexico start-up Avisa Pharma, commercializing a breath test technology developed at the University of New Mexico, participated as a national best university start-up at the National Council of Entrepreneurial Tech Transfer University Startups Demo Day. The event was held at the nation’s capital in Washington DC and included Avisa CEO David Joseph’s testimony at a public hearing of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. To learn more about the company and the event, see Avisa’s press release, posted below, and related article at https://stc.unm.edu/new-mexico-startup-avisa-pharma-chosen-by-national-startup-association-as-a-top-university-company/.
Avisa Selected as a Best University Startup for its Novel BreathTest™ Point-of-Care Diagnostic for Respiratory Infections
Participates in University Startups Demo Day in Washington, DC
CEO David Joseph gives public testimony to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
SANTA FE, N.M. & WASHINGTON: Avisa Pharma Inc. participated this week in the inaugural University Startups Demo Day in Washington, DC, sponsored by the National Council of Entrepreneurial Tech Transfer (NCET2), an association of university startup officers. Avisa was one of only 35 companies selected as a “Best University Startups 2016” company by NCET2 and presented its technology to an audience of Global 1000/Fortune 500 companies, venture capitalists and angel investors looking for investment opportunities. The technology comes out of the University of New Mexico and the program is currently in clinical development at Avisa.
Avisa is a venture-backed healthcare company commercializing a rapid, point-of-care breath test for the diagnosis of pulmonary infections. The Avisa BreathTest™ enables antibiotic stewardship to combat the widespread overuse of antibiotics which has fueled the rise of antibiotic-resistant infections that is estimated to cost the US healthcare system over $20 billion each year1. The lead indication for Avisa’s BreathTest™ is the diagnosis of pneumonia in the emergency department, and a pilot study in that indication is expected to start soon. A second pilot clinical study is also planned for the diagnosis of ventilator-associated pneumonia. Promising results in early clinical studies have been seen in tuberculosis and cystic fibrosis.